One-fifth of late-stage cancer trials changed primary endpoints after trial start, JAMA Network Open study says
Nearly 20% of Phase III clinical trials for cancer therapies had their primary endpoints changed after being publicly reported, according to a study
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
